PNT2002

About Lantheus Medical Imaging

Lantheus Medical Imaging is a leading public radiopharmaceutical company with a mission to 'Find, Fight, and Follow' disease through targeted diagnostic and therapeutic innovations. The company has achieved significant commercial success with products like PYLARIFY for prostate cancer imaging and is aggressively expanding its pipeline through strategic acquisitions and internal R&D into high-growth areas like radiotherapeutics and neurology diagnostics. Its strategy hinges on vertical integration, managing complex radiopharmaceutical logistics, and capitalizing on the growing precision medicine paradigm in nuclear medicine.

About Lantheus Holdings

Lantheus Holdings is a commercial leader in the radiopharmaceutical space, built on a vertically integrated model spanning discovery through global sales. Its strategy is anchored by the commercial success of PYLARIFY®, a leading PSMA PET imaging agent for prostate cancer, and DEFINITY®, an established ultrasound contrast agent. The company is advancing a deep pipeline of approximately 40 programs, targeting expansion in radiopharmaceutical oncology and diagnostics, while leveraging its robust manufacturing and commercial infrastructure to drive growth. With a market cap of ~$4.8B, Lantheus is positioned as a key consolidator and innovator in the high-growth targeted radiopharmaceutical sector.

Therapeutic Areas